Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma

BACKGROUND: The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 years of age with uncontrolled, moderate-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Corren, Jonathan, Katelaris, Constance H., Castro, Mario, Maspero, Jorge F., Humbert, Marc, Halpin, David M.G., Altincatal, Arman, Pandit-Abid, Nami, Soler, Xavier, Radwan, Amr, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584079/
https://www.ncbi.nlm.nih.gov/pubmed/37859672
http://dx.doi.org/10.1183/23120541.00037-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584079/
https://www.ncbi.nlm.nih.gov/pubmed/37859672
http://dx.doi.org/10.1183/23120541.00037-2023

Ejemplares similares